and Mini-Mental State Examination (MMSE) score at baseline. Data presented at AD/PD 2025 showed that LMTX treatment resulted in an 82% reduction in cognitive decline measured by change from baseline ...

mini-mental state examination (MMSE) scores, and Amsterdam – Instrumental Activities of Daily Living (A-IADL) scores. Alzheon also presented brain volume results from the APOLLOE4 trial. In the ...

The University of Washington’s Memory and Brain Wellness Center at Harborview Medical Center has begun treating patients with donanemab, a new Alzheimer’s medication that may slow cognitive ...

A new medication called donanemab appears to slow memory loss, giving patients the gift of more time. UW Medicine's Memory & Brain Wellness Center at Harborview Medical Center recently started ...

Donanemab, made by Eli Lilly and sold under the brand name Kisunla, is not a cure, nor can it reverse memory loss, doctors say. But research has shown that, like its predecessor lecanemab ...

Their results for donanemab showed no binding to the soluble aggregates, suggesting that it preferentially binds to larger insoluble aggregates known as "plaques," which form in the spaces between ...

Since then, other amyloid-targeting monoclonal antibodies, lecanemab and donanemab, have been approved by the US Food and Drug Administration (FDA) for early Alzheimer’s disease. 3 Importantly ...

The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, delaying its review of ...

The Mini-Mental State Examination (MMSE) continues to be the most widely used screening instrument for Alzheimer's disease (AD). However, the test has been criticized along several lines ...

Lilly, which makes the once-monthly anti-amyloid infusion donanemab (Kisunla), announced in late March that patients would be able to quickly access a neurologist for diagnosis via its telehealth ...